NCT00082602View on ClinicalTrials.gov

Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

May 31, 2004

Study Completion Date

April 30, 2005

Conditions
Alzheimer's Disease
Interventions
DRUG

galantamine ER

All Listed Sponsors
collaborator

Ortho-McNeil Neurologics, Inc.

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00082602 - Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease | Biotech Hunter | Biotech Hunter